Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Premier Sponsors:  

Beckman Coulter Life Sciences 

Boston Healthcare


Charles River Discovery




Silicon Biosystems   




  View All Sponsors 

Cambridge Healthtech Institute’s Seventh Annual

Circulating Tumor Cells and Liquid Biopsy

February 20-22, 2017 | Moscone North Convention Center | San Francisco, CA
Part of the 24th International Molecular Medicine Tri-Conference


Molecular traces of cancer can be found in circulation early in the disease. Analysis of biomarker signatures are yielding remarkable insights into early detection, disease progression, therapy monitoring and treatment selection in oncology. Liquid biopsy offers the promise to achieve greater success in our treatment of cancer, but many aspects of this field need to be improved in the isolation and characterization of circulating tumor cells, cell-free circulating DNA, exosomes and extracellular vesicles. This meeting will shed light on novel emerging technologies, analytical validation and clinical implementation. Don’t miss the industry’s leading event on liquid biopsy learn about important discoveries and network with your peers.

Who should attend: Director, Professor, Head of Department, Business Development Manager, Chief Medical Oncologist, Chief Commercial Officer, Chief Scientist, COO, CSO, CEO, Principal Scientist, Program Director, Project Leader, Scientist, Research Director, Fellow, Scientist, Scientific Director, Vice Presidents from Surgery, Internal Medicine, Genitourinary Oncology, Solid Tumor Medicine, Comparative Biomedicine, Genomic Medicine, Personalized Medicine, Therapeutic Systems, Clinical Development, Diagnostics, Molecular Analysis, Chemical Engineering, Molecular & Cellular Biology, Liquid Biopsies, Oncology, Pathology, Interventional Radiology, Chemical Engineering, Biochemistry & Oncology, Tumor Biology, Cancer Biology

Topics will include, but are not limited to:

  • Novel findings with circulating exosomes, extracellular vesicles, RNA and DNA
  • Clinical trial design and recent results
  • Functional analysis of CTCs
  • Propagating cells in vitro
  • CTC markers to predict response to immunotherapy
  • Early cancer detection and recurrence monitoring
  • Comparing CTCs to primary tumor with NGS
  • Harnessing tumor biology and heterogeneity
  • New technologies for liquid biopsy biomarker isolation and characterization

If you would like to submit a proposal to give a presentation at this meeting, click here.

The deadline for submission is July 29, 2016.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:

For partnering and sponsorship information, please contact:

Christina Lingham
Executive Director, Conferences
Cambridge Healthtech Institute
T: (+1) 781-972-5464
E: clingham@healthtech.com

Jon Stroup (Companies A-K)
Senior Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5483
E: jstroup@healthtech.com

Joseph Vacca (Companies L-Z)
Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781.972.5431
E: jvacca@healthtech.com